Ensysce Biosciences
Ensysce Biosciences develops psychedelic-based neuroplastogenic therapies for chronic pain and a novel opioid class designed to minimize abuse and overdose risk.
8-KSep 29Latest SEC filing
Aug 20Latest story
Sign inSign inEnsysce Biosciences develops psychedelic-based neuroplastogenic therapies for chronic pain and a novel opioid class designed to minimize abuse and overdose risk.
August 2026
July 2026